Cassava’s Simufilam: Who to Believe—Wall Street or Alzheimer’s Researchers and Advocates?
By Phil Gutis | February 9th, 2021
Drugmaker Cassava believes its experimental Alzheimer’s therapy, which sent the company’s stock values surging with a recent phase 2 study announcement, could beat Biogen’s…
